Advertisement

Probiotics and Herbal Therapies

  • Agnes Czibulka
Chapter

Abstract

This chapter discusses the evidence for use of probiotics and herbal therapies for treatment of laryngopharyngeal reflux (LPR). An overview of the human microbiome is described. Disease-specific probiotics with specific activity to promote gastrointestinal health may have beneficial effects on symptoms of LPR. The most commonly used probiotics include Lactobacillus, Bifidobacterium, Bacillus, and Streptomyces species. Probiotics are ideally taken as part of the diet and are found in a variety of fermented foods, such as kefir, kimchi, natto, and sauerkraut. Demulcent herbs contain mucilaginous materials that coat the lining of the gastrointestinal tract and can soothe irritation and inflammation. They repair the mucosa by reducing irritation of the bowel and decreasing sensitivity to gastric acid. Aloe vera, licorice root, marshmallow root, and slippery elm root are commonly used demulcent herbs. Other herbs, including Iberogast, ginger, and D-limonene, have been found in clinical studies to reduce gastric acidity, improve gastric emptying, and promote gastric healing. Finally, prolonged proton-pump inhibitor therapy can result in poor absorption of essential nutrients, including calcium, iron, magnesium, and vitamins. Supplementation of these nutrients is necessary to prevent long-term adverse sequelae.

Keywords

Microbiome Probiotic Prebiotic Symbiotic Demulcent herbs Laryngopharyngeal reflux LPR 

References

  1. 1.
    LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol [Internet]. 2013 Apr [cited 2017 Oct 30];24(2):160–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22940212 CrossRefGoogle Scholar
  2. 2.
    Sarkar A, Lehto SM, Harty S, Dinan TG, Cryan JF, Burnet PWJ. Psychobiotics and the manipulation of bacteria-gut-brain signals. Trends Neurosci [Internet]. 2016 Nov [cited 2017 Oct 30];39(11):763–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27793434 CrossRefGoogle Scholar
  3. 3.
    Sherwin E, Sandhu K V, Dinan TG, Cryan JF. May the force be with you: the light and dark sides of the microbiota-gut-brain axis in neuropsychiatry. CNS Drugs [Internet]. 2016 Nov [cited 2017 Oct 30];30(11):1019–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27417321 CrossRefGoogle Scholar
  4. 4.
    Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain–gut–enteric microbiota axis. Nat Rev Gastroenterol Hepatol [Internet]. 2009 May [cited 2017 Oct 30];6(5):306–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19404271 CrossRefGoogle Scholar
  5. 5.
    Foster JA, McVey Neufeld K-A. Gut–brain axis: how the microbiome influences anxiety and depression. Trends Neurosci [Internet]. 2013 May [cited 2017 Oct 30];36(5):305–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23384445
  6. 6.
    Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe [Internet]. 2012 Oct 18 [cited 2017 Oct 30];12(4):496–508. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23084918
  7. 7.
    LILLY DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science [Internet]. 1965 Feb 12 [cited 2017 Oct 30];147(3659):747–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14242024
  8. 8.
    Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea. JAMA [Internet]. 2012 May 9 [cited 2017 Nov 12];307(18):1959. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22570464
  9. 9.
    Yuan F, Ni H, Asche C V., Kim M, Walayat S, Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin [Internet]. 2017 Jul 3 [cited 2017 Nov 12];33(7):1191–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28166427 CrossRefGoogle Scholar
  10. 10.
    Aroniadis OC, Brandt LJ, Greenberg A, Borody T, Kelly CR, Mellow M, et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection. J Clin Gastroenterol [Internet]. 2015 Jun [cited 2017 Nov 12];50(5):1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26125460
  11. 11.
    Francavilla R, Miniello V, Magista AM, De Canio A, Bucci N, Gagliardi F, et al. A randomized controlled trial of lactobacillus GG in children with functional abdominal pain. Pediatrics [Internet]. 2010 Dec 1 [cited 2017 Nov 12];126(6):e1445–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21078735 CrossRefGoogle Scholar
  12. 12.
    Ait-Belgnaoui A, Durand H, Cartier C, Chaumaz G, Eutamene H, Ferrier L, et al. Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology [Internet]. 2012 Nov [cited 2017 Nov 12];37(11):1885–95. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0306453012001291
  13. 13.
    Qin H-L, Shen T-Y, Gao Z-G, Fan X-B, Hang X-M, Jiang Y-Q, et al. Effect of lactobacillus on the gut microflora and barrier function of the rats with abdominal infection. World J Gastroenterol [Internet]. 2005 May 7 [cited 2017 Nov 12];11(17):2591–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15849817 CrossRefGoogle Scholar
  14. 14.
    Indrio F, Riezzo G, Raimondi F, Bisceglia M, Filannino A, Cavallo L, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Investig [Internet]. 2011 Apr [cited 2017 Nov 12];41(4):417–22. Available from: http://doi.wiley.com/10.1111/j.1365-2362.2010.02425.x
  15. 15.
    Garofoli F, Civardi E, Indrio F, Mazzucchelli I, Angelini M, Tinelli C, et al. The early administration of lactobacillus reuteri DSM 17938 controls regurgitation episodes in full-term breastfed infants. Int J Food Sci Nutr [Internet]. 2014 Aug 17 [cited 2017 Nov 12];65(5):646–8. Available from: http://www.tandfonline.com/doi/full/10.3109/09637486.2014.898251 CrossRefGoogle Scholar
  16. 16.
    Waller PA, Gopal PK, Leyer GJ, Ouwehand AC, Reifer C, Stewart ME, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol [Internet]. 2011 Sep 13 [cited 2017 Nov 12];46(9):1057–64. Available from: http://www.tandfonline.com/doi/full/10.3109/00365521.2011.584895 CrossRefGoogle Scholar
  17. 17.
    Raveendra KR, Jayachandra, SV, Sushma KR, Allan JJ, Goudar KS, et al. An extract of Glycyrrhiza glabra (GutGard) alleviates symptoms of functional dyspepsia: a randomized, double-blind, placebo-controlled study. Evid Based Complement Alternat Med [Internet]. 2012 [cited 2017 Nov 12];2012:1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21747893 CrossRefGoogle Scholar
  18. 18.
    van Marle J, Aarsen PN, Lind A, van Weeren-Kramer J. Deglycyrrhizinised liquorice (DGL) and the renewal of rat stomach epithelium. Eur J Pharmacol [Internet]. 1981 Jun 19 [cited 2017 Nov 12];72(2–3):219–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7250207
  19. 19.
    Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity. Phytomedicine [Internet]. 2006 Nov [cited 2017 Oct 30];13:56–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16963243
  20. 20.
    Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol [Internet]. 2007 Jun [cited 2017 Oct 30];102(6):1276–83. Available from: http://www.nature.com/doifinder/10.1111/j.1572-0241.2007.01142.x CrossRefGoogle Scholar
  21. 21.
    Abdel-Aziz H, Zaki HF, Neuhuber W, Kelber O, Weiser D, Khayyal MT. Effect of an herbal preparation, STW 5, in an acute model of reflux oesophagitis in rats. J Pharmacol Sci [Internet]. 2010 [cited 2017 Oct 30];113(2):134–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20484868 CrossRefGoogle Scholar
  22. 22.
    Kandil TS, Mousa AA, El-Gendy AA, Abbas AM. The potential therapeutic effect of melatonin in gastro-esophageal reflux disease. BMC Gastroenterol [Internet]. 2010 Dec 18 [cited 2017 Oct 30];10(1):7. Available from: http://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-10-7
  23. 23.
    Wu K-L, Rayner CK, Chuah S-K, Changchien C-S, Lu S-N, Chiu Y-C, et al. Effects of ginger on gastric emptying and motility in healthy humans. Eur J Gastroenterol Hepatol [Internet]. 2008 May [cited 2017 Oct 30];20(5):436–40. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00042737-200805000-00011
  24. 24.
    Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (lemon balm). Psychosom Med [Internet]. 2004 Jul [cited 2017 Nov 13];66(4):607–13. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006842-200407000-00022
  25. 25.
    Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK, Wesnes KA. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav [Internet]. 2002 Jul [cited 2017 Nov 13];72(4):953–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12062586 CrossRefGoogle Scholar
  26. 26.
    Rozza AL, Moraes T de M, Kushima H, Tanimoto A, Marques MOM, Bauab TM, et al. Gastroprotective mechanisms of Citrus lemon (Rutaceae) essential oil and its majority compounds limonene and β-pinene: involvement of heat-shock protein-70, vasoactive intestinal peptide, glutathione, sulfhydryl compounds, nitric oxide and prostaglandin E2. Chem Biol Interact [Internet]. 2011 Jan [cited 2017 Oct 30];189(1–2):82–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0009279710005776 CrossRefGoogle Scholar
  27. 27.
    Moraes TM, Rozza AL, Kushima H, Pellizzon CH, Rocha LRM, Hiruma-Lima CA. Healing actions of essential oils from Citrus aurantium and d-limonene in the gastric mucosa: the roles of VEGF, PCNA, and COX-2 in cell proliferation. J Med Food [Internet]. 2013 Dec [cited 2017 Oct 30];16(12):1162–7. Available from: http://online.liebertpub.com/doi/abs/10.1089/jmf.2012.0259 CrossRefGoogle Scholar
  28. 28.
    Sun J. D-limonene: safety and clinical applications. Altern Med Rev [Internet]. 2007 Sep [cited 2017 Nov 12];12(3):259–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18072821
  29. 29.
    Yuan YZ, Fang JY, Zou DW, Levinson N, Jenner B, Wilkinson J. Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms. J Dig Dis [Internet]. 2016 Nov [cited 2017 Oct 30];17(11):725–34. Available from: http://doi.wiley.com/10.1111/1751-2980.12406 CrossRefGoogle Scholar
  30. 30.
    Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus [Internet]. 2017 May [cited 2017 Oct 30];30(5):1–9. Available from: https://academic.oup.com/dote/article-lookup/doi/10.1093/dote/dow020 CrossRefGoogle Scholar
  31. 31.
    Rohof WO, Bennink RJ, Smout AJPM, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol [Internet]. 2013 Dec [cited 2017 Oct 30];11(12):1585–91. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1542356513006216 CrossRefGoogle Scholar
  32. 32.
    Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of helicobacter pylori infection: the Maastricht III consensus report. Gut [Internet]. 2007 Jun 1 [cited 2017 Oct 30];56(6):772–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17170018
  33. 33.
    Shikata T, Sasaki N, Ueda M, Kimura T, Itohara K, Sugahara M, et al. Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients. Circ J [Internet]. 2014 [cited 2017 Oct 30];79(1):193–200. Available from: https://www.jstage.jst.go.jp/article/circj/79/1/79_CJ-14-0582/_article CrossRefGoogle Scholar
  34. 34.
    Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf [Internet]. 2013 Jun 25 [cited 2017 Oct 30];4(3):125–33. Available from: http://journals.sagepub.com/doi/10.1177/2042098613482484
  35. 35.
    Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep [Internet]. 2010 Dec 30 [cited 2017 Oct 30];12(6):448–57. Available from: http://link.springer.com/10.1007/s11894-010-0141-0 CrossRefGoogle Scholar
  36. 36.
    Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology [Internet]. 2017 Mar [cited 2017 Oct 30];152(4):821–29.e1. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016508516353926
  37. 37.
    Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail [Internet]. 2015 Aug 9 [cited 2017 Oct 30];37(7):1237–41. Available from: http://www.tandfonline.com/doi/full/10.3109/0886022X.2015.1057800 CrossRefGoogle Scholar
  38. 38.
    Takeda Y, Doyama H, Tsuji K, Yamada S, Takemura K. Does long-term use of proton pump inhibitors cause hypomagnesaemia in Japanese outpatients? BMJ Open Gastroenterol [Internet]. 2014 Jan [cited 2017 Oct 30];1(1):e000003. Available from: http://bmjopengastro.bmj.com/lookup/doi/10.1136/bmjgast-2014-000003
  39. 39.
    Kieboom BCT, Kiefte-de Jong JC, Eijgelsheim M, Franco OH, Kuipers EJ, Hofman A, et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis [Internet]. 2015 Nov [cited 2017 Oct 30];66(5):775–82. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0272638615008367 CrossRefGoogle Scholar
  40. 40.
    Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc [Internet]. 2015 Oct [cited 2017 Oct 30];63(10):2070–3. Available from: http://doi.wiley.com/10.1111/jgs.13661 CrossRefGoogle Scholar
  41. 41.
    Pello Lázaro AM, Cristóbal C, Franco-Peláez JA, Tarín N, Aceña Á, Carda R, et al. Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease. Bugiardini R, editor. PLoS One [Internet]. 2017 Jan 19 [cited 2017 Oct 30];12(1):e0169826. Available from: http://dx.plos.org/10.1371/journal.pone.0169826
  42. 42.
    Sun S, Cui Z, Zhou M, Li R, Li H, Zhang S, et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis. Neurogastroenterol Motil [Internet]. 2017 Feb [cited 2017 Oct 30];29(2):e12926. Available from: http://doi.wiley.com/10.1111/nmo.12926 CrossRefGoogle Scholar
  43. 43.
    Sukhovershin RA, Cooke JP. How may proton pump inhibitors impair cardiovascular health? Am J Cardiovasc Drugs [Internet]. 2016 Jun 27 [cited 2017 Oct 30];16(3):153–61. Available from: http://link.springer.com/10.1007/s40256-016-0160-9
  44. 44.
    Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open [Internet]. 2017 Jun 4 [cited 2017 Oct 30];7(6):e015735. Available from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2016-015735 CrossRefGoogle Scholar
  45. 45.
    Jacob L, Hadji P, Kostev K. The use of proton pump inhibitors is positively associated with osteoporosis in postmenopausal women in Germany. Climacteric [Internet]. 2016 Oct 2 [cited 2017 Oct 30];19(5):478–81. Available from: https://www.tandfonline.com/doi/full/10.1080/13697137.2016.1200549 CrossRefGoogle Scholar
  46. 46.
    Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis [Internet]. 2016 Sep [cited 2017 Oct 30];19(9):864–8. Available from: http://doi.wiley.com/10.1111/1756-185X.12866 CrossRefGoogle Scholar
  47. 47.
    Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA [Internet]. 2006 Dec 27 [cited 2017 Oct 30];296(24):2947. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17190895
  48. 48.
    Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol [Internet]. 2016 Jul [cited 2017 Oct 30];28(4):420–5. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002281-201607000-00013
  49. 49.
    Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med [Internet]. 2002 May [cited 2017 Oct 30];30(5):1118–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12006811 CrossRefGoogle Scholar
  50. 50.
    Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther [Internet]. 2007 Aug 15 [cited 2017 Oct 30];26(4):545–53. Available from: http://doi.wiley.com/10.1111/j.1365-2036.2007.03407.x
  51. 51.
    Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol [Internet]. 2011 Dec [cited 2017 Oct 30];62(6):591–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22314561
  52. 52.
    Moloney RD, Johnson AC, O’Mahony SM, Dinan TG, Greenwood-Van Meerveld B, Cryan JF. Stress and the microbiota-gut-brain Axis in visceral pain: relevance to irritable bowel syndrome. CNS Neurosci Ther [Internet]. 2016 Feb [cited 2017 Oct 30];22(2):102–17. Available from: http://doi.wiley.com/10.1111/cns.12490 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Agnes Czibulka
    • 1
  1. 1.Yale School of Medicine, Department of Surgery, Section of OtolaryngologyENT Medical and Surgical LLCNew HavenUSA

Personalised recommendations